{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:50:25Z","timestamp":1787064625288,"version":"build-2736575974"},"reference-count":31,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,3,10]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The purpose of this study was to determine how strongly mean systolic blood pressure (mSBP, mm Hg) was related to hypertension control and if an mSBP&lt;130 was required to achieve \u226580% control to &lt;140\/&lt;90.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>mSBP and per cent control to &lt;140\/&lt;90 at the last encounter were assessed in a cross-sectional analysis of two cohorts with hypertension: (1) randomised, controlled Systolic blood PRessure Intervention Trial (SPRINT) and (2) real-world American Medical Association\u2019s Measure Accurately, Act Rapidly, Partner with patients Hypertension programme.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>SPRINT randomised participants with hypertension to two SBP targets: &lt;140 (standard treatment, SPRINT-S) and &lt;120 (intensive treatment, SPRINT-I). MAP (Measure Accurately, Act Rapidly, Partner with patients) included adults with hypertension at five healthcare systems incentivised by payers to control BP to &lt;140\/&lt;90.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>SPRINT participants with year 2 data. Patients in MAP (had hypertension, were aged\u226518 years, had \u22652 healthcare visits from November 2019 through October 2021 and received care from clinicians (n=544) with \u226524 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>mSBP and control to &lt;140\/&lt;90. In MAP, control to &lt;140\/&lt;90 was assessed in clinicians grouped by 5 mm Hg increments in the mSBP of their patient panel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In SPRINT-S (n=4303) and SPRINT-I (n=4323), mSBP values at the last visit were 136.7 and 121.7 with BP&lt;140\/&lt;90 in 61% and 88% of participants, respectively. In MAP, mSBP at the last visit (n=168 978 patients) was 132.1 with BP&lt;140\/&lt;90 in 70% of participants. Among clinicians with participant mSBP of 120 to &lt;125, 88% of their patients were controlled to &lt;140\/&lt;90, similar to SPRINT-I. Control fell to 79% of patients, with clinician-level mSBP of 125 to &lt;130, 71%, with mSBP of 130 to &lt;135 and 57%, with mSBP of 135 to &lt;140 (similar to SPRINT-S); mSBP accounted for 80% of variance in clinician-level hypertension control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>mSBP is strongly related to hypertension control. Moreover, mSBP&lt;130 is required to attain control rates to &lt;140\/&lt;90 in the range of 80% and higher.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-090440","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T21:43:09Z","timestamp":1744062189000},"page":"e090440","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Does mean systolic blood pressure less than 130 mm Hg ensure high rates of control to &lt;140\/&lt;90 mm Hg? A cross-sectional analysis of two cohorts"],"prefix":"10.1136","volume":"15","author":[{"given":"Brent","family":"Egan","sequence":"first","affiliation":[{"name":"IHO, American Medical Association, Greenville, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E","family":"Sutherland","sequence":"additional","affiliation":[{"name":"Improving Health Outcomes, American Medical Association, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Martin","sequence":"additional","affiliation":[{"name":"Improving Health Outcomes, American Medical Association, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Riesser","sequence":"additional","affiliation":[{"name":"IHO, American Medical Association, Greenville, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Moran","sequence":"additional","affiliation":[{"name":"Medicine, Columbia University, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[{"name":"George Institute, University of Sydney CAR, Glebe, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rakotz","sequence":"additional","affiliation":[{"name":"Improving Health Outcomes, American Medical Association, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"2025121300015755000_15.4.e090440.1","unstructured":"World Health Organization . Global report on hypertension: the race against a silent killer. Geneva, Switzerland: World Health Organization, 2023:1\u2013276."},{"key":"2025121300015755000_15.4.e090440.2","unstructured":"Tackling high blood pressure: an update. Public Health England, 2018."},{"key":"2025121300015755000_15.4.e090440.3","unstructured":"Million Hearts . Hypertension control challenge. Available: https:\/\/millionhearts.hhs.gov\/partners-progress\/champions\/challenge.html [Accessed 9 Apr 2024]."},{"key":"2025121300015755000_15.4.e090440.4","unstructured":"National Heart Foundation of Australia . Guideline for the diagnosis and management of hypertension in adults\u20132016. Melbourne: National Heart Foundation of Australia, 2016."},{"key":"2025121300015755000_15.4.e090440.5","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066"},{"key":"2025121300015755000_15.4.e090440.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2020.02.086"},{"key":"2025121300015755000_15.4.e090440.7","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003480"},{"key":"2025121300015755000_15.4.e090440.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511939"},{"key":"2025121300015755000_15.4.e090440.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b1665"},{"key":"2025121300015755000_15.4.e090440.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4098"},{"key":"2025121300015755000_15.4.e090440.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12948-0"},{"key":"2025121300015755000_15.4.e090440.12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1161\/HYPERTENSIONAHA.116.07575","article-title":"Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines","volume":"68","author":"Egan","year":"2016","journal-title":"Hypertension"},{"key":"2025121300015755000_15.4.e090440.13","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009480","article-title":"Relationship of Inter-Individual Blood Pressure Variability and the Risk for Recurrent Stroke","volume":"7","author":"Kim","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2025121300015755000_15.4.e090440.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511939"},{"key":"2025121300015755000_15.4.e090440.15","unstructured":"National Heart Lung and Blood Institute . Systolic blood pressure intervention trial (sprint). Biologic Specimen and Data Repository Information Coordinating Center. Available: https:\/\/biolincc.nhlbi.nih.gov\/studies\/sprint\/ [Accessed 16 Jun 2023]."},{"key":"2025121300015755000_15.4.e090440.16","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/HYPERTENSIONAHA.118.11558","article-title":"Improving Hypertension Control in Primary Care With the Measure Accurately, Act Rapidly, and Partner With Patients Protocol","volume":"72","author":"Egan","year":"2018","journal-title":"Hypertension"},{"key":"2025121300015755000_15.4.e090440.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"key":"2025121300015755000_15.4.e090440.18","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.000000000000087"},{"key":"2025121300015755000_15.4.e090440.19","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.22.2673"},{"key":"2025121300015755000_15.4.e090440.20","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/HYPERTENSIONAHA.121.17233","article-title":"Blood Pressure Intervention and Control in SPRINT","volume":"79","author":"Cushman","year":"2022","journal-title":"Hypertension"},{"key":"2025121300015755000_15.4.e090440.21","unstructured":"Healthy People 2020 . Heart disease and stroke. Available: https:\/\/wayback.archive-it.org\/5774\/20220414130735\/https:\/\/www.healthypeople.gov\/2020\/topics-objectives\/topic\/heart-disease-and-stroke\/objectives#4555\/ [Accessed 9 Apr 2024]."},{"key":"2025121300015755000_15.4.e090440.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.297.6644.319"},{"key":"2025121300015755000_15.4.e090440.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.301.6759.1031"},{"key":"2025121300015755000_15.4.e090440.24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5005\/jp-journals-10043-0064","article-title":"Controlling Systolic Blood Pressure below 140 mm Hg in Most Hypertensive Patients matches Systolic Blood Pressure Intervention Trial Intensive Treatment: Practical Implications for Patient Care","volume":"3","author":"Egan","year":"2017","journal-title":"Hypertension Journal"},{"key":"2025121300015755000_15.4.e090440.25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","article-title":"Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension","volume":"77","author":"Parati","year":"2021","journal-title":"Hypertension"},{"key":"2025121300015755000_15.4.e090440.26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.10359"},{"key":"2025121300015755000_15.4.e090440.27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/08037051.2022.2095254","article-title":"Single-pill combinations, hypertension control and clinical outcomes: potential, pitfalls and solutions","volume":"31","author":"Egan","year":"2022","journal-title":"Blood Press"},{"key":"2025121300015755000_15.4.e090440.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01225-8"},{"key":"2025121300015755000_15.4.e090440.29","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000881"},{"key":"2025121300015755000_15.4.e090440.30","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.1421"},{"key":"2025121300015755000_15.4.e090440.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00590-0"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-090440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T08:02:06Z","timestamp":1765612926000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-090440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,7]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bmjopen-2024-090440"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-090440","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}